Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beatrice U Mueller

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Blood|March 11, 2011
Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosisJosé Fos, Thomas Pabst, Vibor Petkovic, et al.
Drug and Alcohol Dependence|November 13, 2019
The maximum alcohol withdrawal syndrome score associates with worse clinical outcomes-A retrospective cohort studyAlexandra N Griessbach, Beatrice U Mueller, Edouard Battegay, et al.
Leukemia Research|January 25, 2015
Consolidation of first remission using radioimmunotherapy with yttrium-90-ibritumomab-tiuxetan in adult patients with Burkitt lymphomaValentin Koechli, Bernd Klaeser, Yara Banz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2008
Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemiaThomas Pabst, Marianne Eyholzer, Simon Haefliger, et al.
European Journal of Internal Medicine|July 26, 2006
A case report of Clarkson's disease: If you don't know it, you'll miss itNicolas Bonadies, Patricia Baud, Hans-Jakob Peter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemiaJulian A Schardt, Daniel Weber, Marianne Eyholzer, et al.
Hematological Oncology|June 5, 2018
Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expressionAlexandra Junge, Ulrike Bacher, Beatrice U Mueller, et al.
Cardiovascular Diagnosis and Therapy|May 19, 2020
Multimorbidity and cardiovascular disease: a perspective on low- and middle-income countriesFriedrich Thienemann, Ntobeko A B Ntusi, Edouard Battegay, et al.
Cancers|June 3, 2018
The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid LeukemiaKatja Seipel, Miguel A T Marques, Corinne Sidler, et al.
Haematologica|July 7, 2018
MDM2- and FLT3-inhibitors in the treatment of <i>FLT3</i>-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurinKatja Seipel, Miguel A T Marques, Corinne Sidler, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Blood|March 11, 2011
Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosisJosé Fos, Thomas Pabst, Vibor Petkovic, et al.
Drug and Alcohol Dependence|November 13, 2019
The maximum alcohol withdrawal syndrome score associates with worse clinical outcomes-A retrospective cohort studyAlexandra N Griessbach, Beatrice U Mueller, Edouard Battegay, et al.
Leukemia Research|January 25, 2015
Consolidation of first remission using radioimmunotherapy with yttrium-90-ibritumomab-tiuxetan in adult patients with Burkitt lymphomaValentin Koechli, Bernd Klaeser, Yara Banz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2008
Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemiaThomas Pabst, Marianne Eyholzer, Simon Haefliger, et al.
European Journal of Internal Medicine|July 26, 2006
A case report of Clarkson's disease: If you don't know it, you'll miss itNicolas Bonadies, Patricia Baud, Hans-Jakob Peter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemiaJulian A Schardt, Daniel Weber, Marianne Eyholzer, et al.
Hematological Oncology|June 5, 2018
Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expressionAlexandra Junge, Ulrike Bacher, Beatrice U Mueller, et al.
Cardiovascular Diagnosis and Therapy|May 19, 2020
Multimorbidity and cardiovascular disease: a perspective on low- and middle-income countriesFriedrich Thienemann, Ntobeko A B Ntusi, Edouard Battegay, et al.
Cancers|June 3, 2018
The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid LeukemiaKatja Seipel, Miguel A T Marques, Corinne Sidler, et al.
Haematologica|July 7, 2018
MDM2- and FLT3-inhibitors in the treatment of <i>FLT3</i>-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurinKatja Seipel, Miguel A T Marques, Corinne Sidler, et al.
Pageof 5